Antibiotic Resistance: New Products and Strategies

Report Highlights

• Worldwide, the total market for new and currently available antibiotics reached $22.3 billion in 2001. Average annual growth rate (AAGR) of 9.1%, this market will climb to $34.5 billion in 2006.
• Growth will be driven by new products, whose sales will rise at an AAGR of more than 50% to $7.4 billion in 2006, representing 21% of the total market.
• Sales in 2001 were just under $1 billion, just 4% of the market.
• In 2001, the market for currently available antibiotics was $21.3 billion and is projected to increase at an AAGR of only 4.9% to $27.2 billion by 2006.
• From 2001 to 2006, some 40 new products or formulations could be introduced into the antibiotics sector.
• Many of these drugs will likely prove effective against infectious disease organisms that have developed multidrug resistances, rejuvenating the antibiotics market.

INTRODUCTION

STUDY GOAL AND OBJECTIVES

This report provides an in-depth look at antibiotic resistance, its causes, the extent of its impact, and strategies to combat it. The report focuses primarily on recently introduced and in-development antibiotic products that specifically address the problem of bacterial resistance. The mechanisms by which these drugs function to outwit resistance microbes are described, as well as the likelihood that resistance will develop and within what timeframe. Drugs that show promise of long-term activity (i.e., low likelihood of resistance) and their effects on the market are assessed. Forecasts of the current antibiotics market by therapeutic category are provided in addition to a forecast of the market for new antibiotic products. Forecasts and trends are gleaned from industry sources as well as from considered assessment of emerging products and technologies.

REASONS FOR DOING THE STUDY

The continuing emergence of antibiotic resistance threatens to reverse the progress made during the latter half of the twentieth century to effectively treat bacterial and other infectious diseases. In 2001, the problem of antimicrobial resistance posed a global threat to the effective treatment of many bacterial diseases. Multidrug-resistant tuberculosis is no longer confined to any one country or to those coinfected with human immunodeficiency virus (HIV). In developed countries, as many as 60% of hospital-acquired infections are caused by drug-resistant microbes. These infections are no longer confined to hospital or nursing home wards but are active in the community at large. In 2001, infections caused by Staphylococcus aureus were responsive to, at most, one drug. Solutions to the dilemma of drug resistance involve management approaches on a worldwide scale (such as the implementation of rigorous surveillance of resistant organisms), better education of health-care workers about appropriate use of antibiotics, and closer monitoring of antibiotics used in animal and plant crops. Dovetailing with these organizational activities is the need for new and effective antibiotic drugs. New antibiotic classes of drugs are being developed, and the first of the products in these new classes are being introduced. This report provides an overview of recently introduced and in-development products, their impact on antibiotic resistance, and their potential impact on the antibiotics market.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

This report provides an explanation of the process of antibiotic resistance and the technologies involved in approaching this challenging and ominous threat. It offers information needed to understand the impact of new products, as well as information on drug resistance monitoring and surveillance efforts in the treatment of bacterial diseases, clinical use, and the marketplace. The report is an invaluable tool for planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investor consultants, and anyone interested in the current and emerging antibiotics market, its products, its industry participants, and its future.

SCOPE AND FORMAT

This report primarily focuses on products in development to treat bacterial diseases, especially those caused by drug-resistant organisms.

• The Overview chapter provides a comprehensive summary of antibiotic resistance, its mechanisms, the most common drug-resistant organisms, and the diseases for which drug resistance is a problem.
• The Products chapter provides detailed discussion of recently introduced novel antibiotic agents and agents in development, how they differ from older products, and their potential impact on treatment and the market.
• The Current Market chapter provides an overview of available products, including preventive vaccines, by therapeutic category, forecasts of sales, and sales trends. The focus is on new classes of products and new technologies in development that specifically address antibiotic drug resistance. Market figures are based on revenues at the manufacturer's level and are projected at 2001 dollar value—that is, inflation is not computed into the projection figures. Trends are assessed based on projected sales for new products and must necessarily be estimates, since the timing of introduction and cost of these agents is not certain. Included in this report are sales for the year 2000 by antibiotic drug class and forecasts from 2001 through 2006, including supporting analyses for projections.
• The Company Profiles chapter provides a close look at companies participating in the "new antibiotics" arena.
• An Appendix of industry-related names and addresses is included at the end of this report.

METHODOLOGY

This report analyzes data supplied by product managers, marketing strategists, research executives, and others at leading companies involved in the development of new antibiotic products. Data was accessed from government agencies and regulatory bodies that monitor and/or regulate pharmaceutical products. Searches of secondary material, such as company annual reports and U.S. Security and Exchange Commission (SEC) 10Ks, journal articles, prospectus assessments, government resources, and data from health-care institutions, were also conducted.

INFORMATION SOURCES

Information to prepare this report was obtained from companies, organizations, and institutions involved in the development of antibiotic products and vaccines, industry analysts, health-care personnel, the National Institute of Allergy and Infectious Diseases, the Centers for Disease Control and Prevention. Also, other government agencies, literature searches, annual reports, SEC 10Ks, and product literature.